iRhythm Technologies Inc
Slēgts
SektorsVeselības aprūpe
110.24 -2.85
Pārskats
Akcijas cenas izmaiņa
24h
Min
111.7
Max
120.03
Ienākumi | 14M -381K |
|---|---|
Pārdošana | 25M 224M |
EPS | 0.58 |
Peļņas marža | -0.17 |
Darbinieki | 2,400 |
EBITDA | 6.5M 2.9M |
Nākamie ieņēmumi | 2026. g. 29. okt. |
|---|
Tirgus kapitalizācija | -40M 4.1B |
|---|---|
Iepriekšējā atvēršanas cena | 113.09 |
Iepriekšējā slēgšanas cena | 110.24 |
Ziņu noskaņojums
By Acuity
12%
88%
12 / 339 Rangs Healthcare
iRhythm Technologies Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
iRhythm Technologies Inc Prognoze
Noskaņojums
By Acuity
12 / 339 Rangs Veselības aprūpe
Ziņu noskaņojums
Ļoti spēcīga liecība "buļļu" tendencei
Volatilitāte
Zem vidējā
Ziņu apjoms (RCV)
Zem vidējā
Finanšu rādītāji
Pārdošanas un administrēšanas izmaksas
Darbības izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
EBITDA
Pamatdarbības peļņa
$
Par iRhythm Technologies Inc
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.